Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow

Doxorubicin is a risk factor for secondary lymphedema in cancer patients exposed to surgery or radiation. The risk is presumed to relate to its cytotoxicity. However, the present study provides initial evidence that doxorubicin directly inhibits lymph flow and this action appears distinct from its c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pharmacol Exp Ther
Main Authors: Stolarz, Amanda J., Sarimollaoglu, Mustafa, Marecki, John C., Fletcher, Terry W., Galanzha, Ekaterina I., Rhee, Sung W., Zharov, Vladimir P., Klimberg, V. Suzanne, Rusch, Nancy J.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society for Pharmacology and Experimental Therapeutics 2019
Assuntos:
Cardiovascular
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6815939/
https://ncbi.nlm.nih.gov/pubmed/31439806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.257592
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados